AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
09 Sep 2019
Small Cap Feast
Oncimmune Holdings Plc (ONC:LON), 27.6 | Pennant International Group plc (PEN:LON), 28.5 | Reabold Resources plc (RBD:LON), 0.1 | United Oil & Gas Plc (UOG:LON), 0.2 | SIMEC Atlantis Energy Ltd. (SAE:LON), 0.8 | Petro Matad Limited (MATD:LON), 3.9 | Cerillion Plc (CER:LON), 1,470 | Mosman Oil & Gas Ltd. (MSMN:LON), 0.0 | Mercantile Ports & Logistics Limited (MPL:LON), 1.8
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
Oncimmune Holdings Plc (ONC:LON), 27.6 | Pennant International Group plc (PEN:LON), 28.5 | Reabold Resources plc (RBD:LON), 0.1 | United Oil & Gas Plc (UOG:LON), 0.2 | SIMEC Atlantis Energy Ltd. (SAE:LON), 0.8 | Petro Matad Limited (MATD:LON), 3.9 | Cerillion Plc (CER:LON), 1,470 | Mosman Oil & Gas Ltd. (MSMN:LON), 0.0 | Mercantile Ports & Logistics Limited (MPL:LON), 1.8
- Published:
09 Sep 2019 -
Author:
Derren Nathan - Pages:
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019